{"nctId":"NCT02810457","briefTitle":"Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer","startDateStruct":{"date":"2016-09-07","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"count":731,"armGroups":[{"label":"FKB238 / paclitaxel / carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: FKB238 (bevacizumab)","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Avastin / paclitaxel / carboplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Avastin (bevacizumab)","Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"name":"FKB238 (bevacizumab)","otherNames":[]},{"name":"Avastin (bevacizumab)","otherNames":[]},{"name":"Paclitaxel","otherNames":[]},{"name":"Carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease\n* Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC\n* Existence of at least 1 measurable lesion by RECIST v1.1\n* Adequate hematological, renal and liver function\n* Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1\n* Life expectancy longer than 6 months\n\nExclusion Criteria:\n\n* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature\n* Any unresolved toxicities from prior systemic therapy\n* Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations\n* Previous dosing with vascular endothelial growth factor (VEGF) inhibitor\n* Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy\n* Use of prohibited concomitant medication\n* Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection\n* Fertile men or women of childbearing potential not using adequate contraception.\n\nOther inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR)","description":"The primary variable in this study was ORR, defined as the proportion of patients with a BOR of CR or PR (by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)). A BOR was defined as the best response (in the order of CR, PR, stable disease (SD), no evidence of disease (NED), progressive disease (PD), and not evaluable (NE)) among all post-baseline disease assessments that occurred until progression, or last evaluable assessment in the absence of progression prior to the initiation of subsequent anti-cancer therapy, irrespective of whether or not patients discontinued the study treatment. The 95% Pearson-Clopper confidence interval (CI) of ORR for each treatment arm was provided. Per RECIST v1.1 for target lesions and assessed by computed tomography (CT) or, if contraindicated, magnetic resonance imaging (MRI): CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. Overall Response=CR+PR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null},{"groupId":"OG001","value":"53.7","spread":null}]}]}]},{"type":"SECONDARY","title":"ORR at Week 19","description":"ORR (by RECIST v1.1) at Week 19 was defined as the proportion of patients with a BOR of CR or PR assessed at Week 19. Only tumor assessments performed up until 19 weeks (i.e. Week 18 assessment + 7 day assessment window) from randomization were considered in this analysis. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. Overall Response=CR+PR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"51.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"The event of interest for PFS was defined as the interval from the date of randomization until first documented disease progression or death from any cause, whichever occurs first. Disease progression was based on tumor assessments according to RECIST v1.1 criteria. The items of the overall response CR, PR, SD and NED were taken as progression-free whereas PD denoted disease progression. PFS was summarized using Kaplan-Meier estimates of the quartiles for each treatment arm, and 95% CIs for the medians were calculated. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: PD=at least a 20% increase in the sum of the longest diameter of target lesions, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.72","spread":null},{"groupId":"OG001","value":"7.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The event of interest was defined as death from any cause. OS was defined as the interval from date of randomization until the date of death due to any cause. OS was summarized using Kaplan-Meier estimates of the quartiles for each treatment arm, and 95% CIs for the medians were calculated.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.13","spread":null},{"groupId":"OG001","value":"16.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration Of Response (DOR)","description":"DOR was evaluated in this study as a secondary efficacy endpoint. Only the patients defined as responders in the primary analysis of ORR were taken into account for the analysis of DOR. The event of interest was defined as first documented disease progression or death due to any reason, whichever occurred first. DOR was defined as the interval from the first documented response (as defined per RECIST v1.1) until the earlier date of the first documented disease progression or death due to any reason. The date of first documented response was taken as the date of the first tumor assessment with an overall visit response of CR or PR. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. DOR was calculated in units of months.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":null},{"groupId":"OG001","value":"6.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) Assessed as the Proportion of Patients With a BOR of Either CR, PR, SD or NED","description":"The DCR was defined as the proportion of patients defined as responders. The number and percentage of responders and non-responders and the 95% Pearson-Clopper CI of DCR for each treatment arm was provided. The odds ratio for treatment (FKB238 arm versus Avastin arm) and the corresponding 95% Wald CI were produced based on a logistic regression analysis of DCR. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. DCR=CR+PR+SD (â‰¥ 6 weeks).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serum Trough Concentration (Ctrough)","description":"Ctrough (pre-infusion) and serum maximum concentration (Cmax; at completion of infusion) were compared between treatment arms and time points, and descriptive statistics provided. Ctrough and Cmax concentrations were summarized using the pharmacokinetics (PK) population for each visit at which samples were taken. The pre-dose serum concentrations at Cycles 2, 4, and 6 were considered as Ctrough values and the post-dose serum concentrations at Cycles 1 and 4 were considered as Cmax values. PK data at Cycle 1 Day 1 pre-infusion were not calculable and are therefore not presented in the outcome measure data table. Data are only provided for the time points at which the serum trough concentration was measured.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255.15","spread":"184.3"},{"groupId":"OG001","value":"245.11","spread":"206.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.74","spread":"91.9"},{"groupId":"OG001","value":"48.48","spread":"77.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.16","spread":"69.4"},{"groupId":"OG001","value":"83.26","spread":"85.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339.91","spread":"91.3"},{"groupId":"OG001","value":"373.92","spread":"51.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.25","spread":"124.5"},{"groupId":"OG001","value":"108.22","spread":"69.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Patients Developing Anti-drug Antibodies (ADAs)","description":"The ADA levels were summarized at baseline and post-baseline time points using descriptive statistics.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events (AEs)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Vital Signs","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Hematology","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Clinical Chemistry","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Urinalysis","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Electrocardiogram","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Eastern Collaborative Oncology Group Performance Status","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Physical Examination","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":91,"n":362},"commonTop":["Alopecia","Neutropenia","Anaemia","Thrombocytopenia","Neuropathy peripheral"]}}}